GeneTether Therapeutics (XCNQ:GTTX) EV-to-EBIT : 0.88 (As of May. 23, 2024)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GeneTether Therapeutics's Enterprise Value is C$-0.89 Mil. GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.01 Mil. Therefore, GeneTether Therapeutics's EV-to-EBIT for today is 0.88.

The historical rank and industry rank for GeneTether Therapeutics's EV-to-EBIT or its related term are showing as below:

XCNQ:GTTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.6 Med: 0 Max: 0.9
Current: 0.9

During the past 4 years, the highest EV-to-EBIT of GeneTether Therapeutics was 0.90. The lowest was -31.60. And the median was 0.00.

XCNQ:GTTX's EV-to-EBIT is ranked better than
69.74% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs XCNQ:GTTX: 0.90

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. GeneTether Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$-0.28 Mil. GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.01 Mil. GeneTether Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 359.01%.

GeneTether Therapeutics EV-to-EBIT Historical Data

The historical data trend for GeneTether Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics EV-to-EBIT Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-1.03

0.28

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial								-1.03	-0.07	0.29	0.12	0.28

Competitive Comparison of GeneTether Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, GeneTether Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneTether Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's EV-to-EBIT falls into.

GeneTether Therapeutics EV-to-EBIT Calculation

GeneTether Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-0.889	/	-1.006
	=	0.88

GeneTether Therapeutics's current Enterprise Value is C$-0.89 Mil.
GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.01 Mil.

GeneTether Therapeutics (XCNQ:GTTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GeneTether Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-1.006	/	-0.280212
	=	359.01 %

GeneTether Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$-0.28 Mil.
GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.01 Mil.

GeneTether Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines